Patent · US Active

Fusion constructs and methods of using thereof

US12194094B2 · kind B2 · utility

0Cited by

9References

15Claims

0Family size

Assignee

Precigen, Inc. · US

Inventors

Helen Sabzevari · Blacksburg, US
Simon METENOU · Germantown, US
Chang-Hung Chen · Tainan, TW
Rutul Shah · Boyds, US

Key dates

Filing date	Jul 9, 2021
Grant date	Jan 14, 2025
Priority date	—
Expiry date	Apr 4, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-β trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.